Neuroges said that in November 2009, Qutenza was approved by the FDA for the management of neuropathic pain associated with PHN. Qutenza is the prescription-strength topical treatment for PHN to be approved by the FDA in more than 10 years. It harnesses the power of capsaicin in a dermal delivery system that targets the nerves in the skin. It is locally-acting and non-narcotic, and unlikely to cause drowsiness or interact with other drugs. It can be used alone or with other pain medications.
The active ingredient in Qutenza is a synthetic form of capsaicin, a naturally occurring compound found in chili peppers that gives them their heat sensation. Qutenza is applied directly to the painful site by a physician or health care professional under the close supervision of a physician.
Up to four Qutenza patches may be used and patches may be cut to conform to the size and shape of the painful area. According to Neuroges, treatment with Qutenza may be repeated every three or more months as warranted by the return of pain, but not more frequently than every three months.
Lynn Webster, medical director of Lifetree Clinical Research at Salt Lake City, Utah, said: “Qutenza may provide a unique treatment option for PHN patients. It is targeted directly to the site of the pain and may be used alone or in combination with existing therapies.”
Anthony DiTonno, president and chief executive officer, NeurogesX, said: “We are delighted to make Qutenza available for the many patients suffering from PHN and for the physicians looking for new ways to manage post-shingles pain. At NeurogesX, we have been committed to developing novel pain management therapies based on the power of prescription-strength capsaicin.
“Qutenza, which can provide patients with three months of pain relief, bears witness to the efficacy of capsaicin and the culmination of 10 years of work to bring this product to market for the benefit of PHN patients.”